Lerimamed (Hydrochlorothiazide, Ramipril)

Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urine output and lowering blood volume. Ramipril blocks the angiotensin‑converting enzyme, reducing angiotensin II production and relaxing blood vessels. Together they lower blood pressure and enhance fluid elimination.

The dose of Lerimamed is individualized by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, and overall health. The prescriber determines the appropriate strength and frequency, and patients should follow the written prescription without alteration.

Lerimamed is classified as Pregnancy Category D, indicating evidence of fetal risk and it should be avoided during pregnancy. Safety during breastfeeding has not been established, so the medication is generally not recommended for nursing mothers unless the benefits outweigh the risks.

To request Lerimamed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lerimamed combines an ACE inhibitor with a thiazide diuretic, offering dual mechanisms in a single tablet. Compared with monotherapy, the combination can achieve better blood‑pressure control and may simplify dosing. It differs from ARB‑diuretic combos by using an ACE inhibitor, which may cause cough but provides proven cardiovascular protection.

Store Lerimamed at room temperature, below 25 °C, in the original container to protect it from moisture and light. Keep the tablet out of reach of children and do not use if the packaging is damaged or the product appears discolored.

Lerimamed is taken orally, usually once daily or as directed by the prescriber. The tablet should be swallowed whole with a full glass of water, and it can be taken with or without food unless the doctor advises otherwise.

Serious risks include angioedema (rapid swelling of the face, lips, tongue or throat), severe dehydration or hypotension, hyperkalemia, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden weakness, or a marked drop in urine output.

Lerimamed should be avoided in patients with known hypersensitivity to either component, those with severe renal impairment, hyperkalemia, or a history of angioedema related to ACE‑inhibitor therapy. It is also contraindicated during pregnancy and should be used with caution in the elderly.